Melanoma vaccine combination shows numerical benefit but misses primary endpoint, shares plummet 34% IO Biotech’s Phase 3 trial evaluating its IO102/IO103 therapeutic cancer vaccine (Cylembio)
Thermo Fisher’s companion diagnostic enables precision treatment with zongertinib for rare NSCLC subset The FDA approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a
Phase 3 trial demonstrates practice-changing survival benefits in muscle-invasive disease Pfizer announced highly positive interim results from a pivotal Phase 3 trial combining its antibody-drug
HistoSonics has secured a transformative investment that values the innovative medical device company at $2.25 billion, with a consortium led by Johnson & Johnson Development
Strand Therapeutics has raised an impressive $153 million in funding to advance its pioneering programmable mRNA cancer therapy platform, with backing from pharmaceutical giants Amgen
Jazz Pharmaceuticals has achieved a groundbreaking milestone in pediatric oncology with the FDA approval of Modeyso (vorasidenib), marking the first systemic treatment specifically approved for
Quick Summary Investment: Sanofi has invested $300 million for a 16% stake in OranoMed. Partnership Focus: Developing radiopharmaceuticals for targeted cancer treatment. Impact: Expands Sanofi’s
Quick Summary Acquisition Value: $250 million Strategic Focus: Expanding Telix’s manufacturing and radiopharmaceutical presence in the U.S. Impact: Enhances Telix’s capabilities in producing radiopharmaceuticals for
Quick Summary Focus: Nanocube Health Ltd. is developing nanorobots for diagnosing and treating hard-to-detect cancers. Initial Target: Pancreatic cancer, known for its high mortality and
Quick Summary Acquisition Value: Veracyte acquired C2i Genomics for $70 million, with an additional $25 million contingent on performance milestones. Strategic Goal: To expand Veracyte’s
